HK1222565A1 - 高效糖皮質激素 - Google Patents

高效糖皮質激素 Download PDF

Info

Publication number
HK1222565A1
HK1222565A1 HK16110801.0A HK16110801A HK1222565A1 HK 1222565 A1 HK1222565 A1 HK 1222565A1 HK 16110801 A HK16110801 A HK 16110801A HK 1222565 A1 HK1222565 A1 HK 1222565A1
Authority
HK
Hong Kong
Prior art keywords
compound
group
alkyl
heteroaryl
aryl
Prior art date
Application number
HK16110801.0A
Other languages
English (en)
Chinese (zh)
Inventor
Huaqiang Eric Xu
Yuanzheng He
Karsten Melcher
Wei Yi
Jingjing Shi
Original Assignee
范安德尔研究所
中国科学院上海药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 范安德尔研究所, 中国科学院上海药物研究所 filed Critical 范安德尔研究所
Publication of HK1222565A1 publication Critical patent/HK1222565A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Epidemiology (AREA)
HK16110801.0A 2013-09-25 2014-09-25 高效糖皮質激素 HK1222565A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361882444P 2013-09-25 2013-09-25
US61/882,444 2013-09-25
PCT/US2014/057497 WO2015048316A1 (en) 2013-09-25 2014-09-25 Highly potent glucocorticoids

Publications (1)

Publication Number Publication Date
HK1222565A1 true HK1222565A1 (zh) 2017-07-07

Family

ID=52744465

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110801.0A HK1222565A1 (zh) 2013-09-25 2014-09-25 高效糖皮質激素

Country Status (9)

Country Link
US (1) US9975918B2 (https=)
EP (1) EP3049089B1 (https=)
JP (1) JP2016531852A (https=)
KR (1) KR20160060688A (https=)
CN (2) CN113845558A (https=)
AU (1) AU2014324961A1 (https=)
ES (1) ES2751457T3 (https=)
HK (1) HK1222565A1 (https=)
WO (1) WO2015048316A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
EP3525870B1 (en) * 2016-10-14 2023-05-10 Van Andel Research Institute Highly potent glucocorticoids
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
CN117024499A (zh) * 2023-07-17 2023-11-10 陕西汉江药业集团股份有限公司 在2位引入亚甲基羟基的甾体化合物制备方法
CN120365344A (zh) * 2024-01-24 2025-07-25 浙江柏拉阿图医药科技有限公司 一种高效力糖皮质激素化合物及其制备和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049813A (en) 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
WO2002102807A1 (en) 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
GB0119911D0 (en) 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
EA201000436A1 (ru) 2007-10-04 2010-10-29 Астразенека Аб Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
CN102361640B (zh) 2009-01-13 2016-10-19 范安德尔研究所 异噁唑吡啶酮在制备用于缓解或减轻温血哺乳动物关节炎和哮喘的症状的药物中的用途
UY32525A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32523A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
CN102834406A (zh) * 2009-06-16 2012-12-19 默沙东公司 作为糖皮质激素受体激动剂的新的[3.2-c]杂芳基甾体、其组合物和用途

Also Published As

Publication number Publication date
EP3049089B1 (en) 2019-08-21
EP3049089A4 (en) 2017-08-09
EP3049089A1 (en) 2016-08-03
US20160251393A1 (en) 2016-09-01
CN105744937A (zh) 2016-07-06
US9975918B2 (en) 2018-05-22
CN113845558A (zh) 2021-12-28
ES2751457T3 (es) 2020-03-31
JP2016531852A (ja) 2016-10-13
WO2015048316A1 (en) 2015-04-02
KR20160060688A (ko) 2016-05-30
AU2014324961A1 (en) 2016-04-14
AU2014324961A8 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
HK1222565A1 (zh) 高效糖皮質激素
CN101454005B (zh) 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物
KR20220101075A (ko) Il-17a 조절인자 및 이의 용도
JP6689856B2 (ja) ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用
CN106008488B (zh) 氰基吲哚类衍生物及其制备方法和用途
UA121658C2 (uk) Сполуки 5-хлордифторметоксифенілпіразолопіримідину як інгібітори янус-кінази
EP3174882B1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
JP2013514367A (ja) 代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩
CA3237467A1 (en) Lactams as cbl-b inhibitors selective over c-cbl
JP2022132464A (ja) 非常に強力な糖質コルチコイドの構造およびデザインのための機構
CN105308037A (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
JP2014515741A (ja) オーレオバシジウム誘導体および合成方法
TW201629025A (zh) 化合物及其作為ｂａｃｅ抑制劑之用途
HK40070300A (en) Highly potent glucocorticoids
CN107089955B (zh) 磺酰胺类衍生物及其制备方法和用途
HK40017057A (en) Structures and mechanism for the design of highly potent glucocorticoids
HK40017057B (zh) 用於设计高效力糖皮质激素的结构与机制
WO2025157225A1 (zh) 一种高效力糖皮质激素化合物及其制备和用途
HK40074980A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
CN121843943A (zh) 一种化合物、及其药物组合物和应用
CN107540672A (zh) 一种治疗肝硬化的药物及其合成方法